Eyepoint Pharmaceuticals Inc Strategic Asset Allocation Index
Eyepoint Pharmaceuticals Inc strategic asset allocation index. Eyepoint Pharmaceuticals Inc (EYPT) has a Strategic Asset Allocation Index of 5.0% as of June 2023. Strategic assets (PP&E of $2.87 Million plus long-term investments of $-) total $2.87 Million, measured against net assets of $57.26 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See EYPT equity to assets ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Eyepoint Pharmaceuticals Inc (2002–2022)
Strategic asset allocation index of Eyepoint Pharmaceuticals Inc from 2002 to 2022. This chart shows how Eyepoint Pharmaceuticals Inc's Strategic Asset Allocation Index has evolved across 21 annual periods from 2002 to 2022. As of June 2023, the index stands at 5.0%, representing strategic assets of $2.87 Million against net assets of $57.26 Million USD. Check tangible net worth ratio of Eyepoint Pharmaceuticals Inc to evaluate the tangible quality of the company's equity base.
Eyepoint Pharmaceuticals Inc Strategic Asset Allocation Index by Year (2002–2022)
Eyepoint Pharmaceuticals Inc strategic asset allocation index by year from 2002 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Eyepoint Pharmaceuticals Inc from 2002 to 2022, covering 21 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see EYPT stock market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 1.4% | $1.36 Million | $1.36 Million | $- | $96.37 Million | ▲ +0.2 pp |
| 2021 | 1.2% | $2.25 Million | $2.25 Million | $- | $184.38 Million | ▼ -2.2 pp |
| 2020 | 3.4% | $630.00K | $630.00K | $- | $18.54 Million | ▼ -0.9 pp |
| 2019 | 4.3% | $357.00K | $357.00K | $- | $8.33 Million | ▲ +1.8 pp |
| 2018 | 2.5% | $288.00K | $288.00K | $- | $11.69 Million | ▲ +0.6 pp |
| 2017 | 1.9% | $253.00K | $253.00K | $- | $13.34 Million | ▲ +0.4 pp |
| 2016 | 1.5% | $313.00K | $313.00K | $- | $20.88 Million | ▲ +0.3 pp |
| 2015 | 1.2% | $290.00K | $290.00K | $- | $23.37 Million | ▼ -1.0 pp |
| 2014 | 2.3% | $338.00K | $338.00K | $- | $14.92 Million | ▼ -1.6 pp |
| 2013 | 3.9% | $297.00K | $297.00K | $- | $7.70 Million | ▲ +2.5 pp |
| 2012 | 1.3% | $179.00K | $179.00K | $- | $13.64 Million | ▲ +0.4 pp |
| 2011 | 0.9% | $335.00K | $335.00K | $- | $37.43 Million | ▲ +0.5 pp |
| 2010 | 0.4% | $123.00K | $123.00K | $- | $33.04 Million | ▲ +0.2 pp |
| 2009 | 0.2% | $43.00K | $43.00K | $- | $23.54 Million | ▼ -0.1 pp |
| 2008 | 0.3% | $66.00K | $66.00K | $- | $21.79 Million | ▼ -0.4 pp |
| 2007 | 0.7% | $473.00K | $473.00K | $- | $65.91 Million | ▼ -0.1 pp |
| 2006 | 0.8% | $512.00K | $512.00K | $- | $66.20 Million | ▼ -3.1 pp |
| 2005 | 3.8% | $2.33 Million | $2.33 Million | $- | $60.74 Million | ▼ -0.3 pp |
| 2004 | 4.1% | $2.49 Million | $2.49 Million | $- | $60.74 Million | ▲ +2.4 pp |
| 2003 | 1.7% | $466.00K | $466.00K | $- | $26.70 Million | ▼ -4.7 pp |
| 2002 | 6.4% | $271.00K | $271.00K | $- | $4.23 Million | — |